I-Mab Presents Promising Phase 1b Givastomig Combination Data for Gastric Cancers at ESMO GI 2025

finance.yahoo.com/news/mab-presents-promising-phase-1b-112004537.html

In This Article:
I-Mab (NASDAQ:IMAB) is one of the best-performing NASDAQ stocks according to analysts. On July 2, I-Mab announced the presentation of positive Phase 1b combination data for givastomig at the European Society for Medical Oncology Gastrointestinal Cancers Congress 2025…

This story appeared on finance.yahoo.com, 2025-07-09 11:20:04.
The Entire Business World on a Single Page. Free to Use →